(RTTNews) - Immuneering Corp. (IMRX), Tuesday announced positive data update from three arms of its ongoing Phase 2a trial of lead program IMM-1-104 for the treatment of patients with Pancreatic ...
We are a made to order company. Most of our apparel items are printed right here in Savannah, GA! Please allow 3-5 business days for your order to be shipped. Limited Time Designs will ship on their ...
Shares of Immuneering Corporation (NASDAQ:IMRX) surged 55% following the release of encouraging data from its ongoing Phase 2a trial of IMM-1-104, a therapy for pancreatic cancer. The Cambridge-based ...
Each of the two parts of the Phase 2a trial of DA-1241 were designed to be ... These patients were enrolled in either Part 1, which is exploring the efficacy of DA-1241 versus placebo, and ...
and camera improvements to the Nothing Phone (1) and Phone (2a) Plus. You can check the complete changelog below for more details. Use widgets to link up with friends and family. See another ...
Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company, made waves in the stock market this week, with its stock price surging a staggering 133.90% to $5.52 during Tuesday’s ...
In a community post, Nothing has shared the arrival of Circle to Search on its latest phones. They include the Phone 2, Phone 2a, and Phone 2a Plus, all of which have received stable Android 15 ...